Christenson Eric S, Tsai Hua-Ling, Le Dung T, Jaffee Elizabeth M, Dudley Jonathan, Xian Rena R, Gocke Christopher D, Eshleman James R, Lin Ming-Tseh
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, United States.
The Cancer Convergence Institute at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Front Oncol. 2023 Jun 7;13:1193259. doi: 10.3389/fonc.2023.1193259. eCollection 2023.
The highest incidence of colorectal cancer (CRC) is in patients diagnosed at 80 years or older highlighting a need for understanding the clinical and molecular features of these tumors. Methods. In this retrospective cohort study, 544 CRCs underwent next generation sequencing and mismatch repair (MMR) evaluation. Molecular and clinical features were compared between 251 patients with traditional-onset CRC (50-69 years at diagnosis) and 60 with late-onset CRC (>80 years at diagnosis).
Late-onset CRC showed a significantly higher rate of right-sided tumors (82% vs 35%), MMR deficiency (35% vs. 8%) and p.V600E mutations (35% vs. 8%) and a significantly lower rate of stage IV disease (15% vs 28%) and mutations (52% vs. 78%). Association of these features with advanced age was supported by stratifying patients into 6 age groups (<40, 40-49, 50-59, 60-69, 70-79 and >80 years). However, the age-related rise in MMR deficient (dMMR) CRC was only seen in the female patients with an incidence of 48% (vs. 10% in the male patient) in the >80y group. In addition, p.V600E was significantly enriched in MMR deficient CRC of advanced age (67% in late-onset CRC). Categorizing CRC by mutational profiling, late-onset CRC revealed a significantly higher rate of dMMR/ (18% vs. 2.0%), dMMR/ (8.3% vs. 1.2%) and MMR proficient (pMMR)/ (12% vs. 4.0%) as compared to traditional-onset CRC.
In summary, there was a higher rate of dMMR and p.V600E in late-onset CRC, independently or in combination. The higher incidence of dMMR in late-onset CRC in females is most likely predominantly driven by p.V600E induced hypermethylation. Prospective studies with treatment plans designed specifically for these older patients are warranted to improve their outcomes.
结直肠癌(CRC)的最高发病率出现在80岁及以上被诊断出的患者中,这凸显了了解这些肿瘤的临床和分子特征的必要性。方法。在这项回顾性队列研究中,对544例结直肠癌进行了下一代测序和错配修复(MMR)评估。比较了251例传统发病型结直肠癌患者(诊断时年龄为50 - 69岁)和60例晚发型结直肠癌患者(诊断时年龄>80岁)的分子和临床特征。
晚发型结直肠癌显示右侧肿瘤的发生率显著更高(82%对35%)、MMR缺陷率(35%对8%)和p.V600E突变率(35%对8%),而IV期疾病的发生率显著更低(15%对28%)以及突变率(52%对78%)。将患者分为6个年龄组(<40岁、40 - 49岁、50 - 59岁、60 - 69岁、70 - 79岁和>80岁),支持了这些特征与高龄的相关性。然而,MMR缺陷(dMMR)结直肠癌的年龄相关上升仅在女性患者中可见,在>80岁组中发生率为48%(男性患者为10%)。此外,p.V600E在高龄dMMR结直肠癌中显著富集(晚发型结直肠癌中为67%)。通过突变谱对结直肠癌进行分类,与传统发病型结直肠癌相比,晚发型结直肠癌显示dMMR/ (18%对2.0%)、dMMR/ (8.3%对1.2%)和MMR proficient(pMMR)/ (12%对4.0%)的发生率显著更高。
总之,晚发型结直肠癌中dMMR和p.V600E的发生率更高,无论是单独还是联合出现。晚发型结直肠癌女性中dMMR发生率较高很可能主要是由p.V600E诱导的高甲基化驱动的。有必要进行前瞻性研究,制定专门针对这些老年患者的治疗方案,以改善他们的治疗效果。